Market open

Cartesian Therapeutics/$RNAC

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Ticker

$RNAC
Trading on

Industry

Biotechnology

Employees

38

RNAC Metrics

BasicAdvanced
$422M
Market cap
-
P/E ratio
-$23.08
EPS
-
Beta
-
Dividend rate
$422M
$42.60
$11.67
104K
10.705
10.512
1,579.92
1,948.271
-10.95%
-7,029.26%
4.245
528.14
-2.01
-4.204
-62.40%

What the Analysts think about RNAC

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.

RNAC Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RNAC Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RNAC

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cartesian Therapeutics stock?

Cartesian Therapeutics (RNAC) has a market cap of $422M as of November 22, 2024.

What is the P/E ratio for Cartesian Therapeutics stock?

The price to earnings (P/E) ratio for Cartesian Therapeutics (RNAC) stock is 0 as of November 22, 2024.

Does Cartesian Therapeutics stock pay dividends?

No, Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next Cartesian Therapeutics dividend payment date?

Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders.

What is the beta indicator for Cartesian Therapeutics?

Cartesian Therapeutics (RNAC) does not currently have a Beta indicator.